Preface

Advanced Drug Delivery Reviews

Volumn 19, Issue 2, 1996, Pages 111-114

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

PRODRUG;

BLOOD BRAIN BARRIER; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; ECONOMIC ASPECT; LIPID SOLUBILITY; MEDICAL RESEARCH; MEMBRANE PERMEABILITY; NOTE; PRIORITY JOURNAL;

EID: 0030008526     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)90027-7     Document Type: Editorial

References (10)

1. A.A. Sinkula S.J. Yalkowsky Rationale for the design of biologically reversible derivatives: prodrugs J. Pharm. Sci. 64 1975 181 210
2. T. Higuchi V. Stella Pro-drugs as Novel Drug Delivery Systems 3rd Edn ACS Symposium Series 14 1975 American Chemical Society Washington, DC
3. E.B. Roche Design of Biopharmaceutical Properties through Prodrugs and Analogs 1977 American Pharmaceutical Association Washington, DC
4. H. Bundgaard Design of Prodrugs 1985 Elsevier Amsterdam
5. H. Bundgaard Themed issue. Prodrugs for Improved Drug Delivery Adv. Drug Deliv. Rev. 3 1989 1 154
6. K.B. Sloan Prodrugs: Topical and Ocular Drug Delivery 1992 Marcel Dekker Inc New York, NY
7. E.H. Ulm Enalaril maleate (MK-421), a potent nonsulfhydryl angiotensin-converting enzyle inhibitor: Absorption, disposition, and metabolism in man Drug Metab. Dispos. 14 1983 99 110
8. P. Dellamonica Cefuroxime axetil Int. J. Antimicrob. Agents. 4 1994 23 36 and references therein
9. V.J. Stella A case for prodrugs: fosphenytoin Adv. Drug Deliv. Rev. 1996
10. A. Albert Selective Toxicity 3rd Edn 1965 Wiley New York